Apotea (APOTEA) - Net Assets

Latest as of June 2026: Skr962.80 Million SEK ≈ $103.61 Million USD

Based on the latest financial reports, Apotea (APOTEA) has net assets worth Skr962.80 Million SEK (≈ $103.61 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr2.23 Billion ≈ $239.53 Million USD) and total liabilities (Skr1.26 Billion ≈ $135.92 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Apotea balance sheet independence to measure how much of total assets are equity-financed.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr962.80 Million
% of Total Assets	43.26%
Annual Growth Rate	26.13%
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	615.76

Apotea - Net Assets Trend (2021–2025)

This chart illustrates how Apotea's net assets have evolved over time, based on quarterly financial data. Also explore how fast is Apotea growing its equity to track the company's year-over-year net asset growth rate.

Annual Net Assets for Apotea (2021–2025)

The table below shows the annual net assets of Apotea from 2021 to 2025. For live market cap and overall valuation, see Apotea (APOTEA) market capitalisation.

Year	Net Assets	Change
2025-12-31	Skr859.90 Million ≈ $92.54 Million	+1402.27%
2024-12-31	Skr57.24 Million ≈ $6.16 Million	+36.16%
2023-12-31	Skr42.04 Million ≈ $4.52 Million	-88.16%
2022-12-31	Skr355.00 Million ≈ $38.20 Million	+4.49%
2021-12-31	Skr339.76 Million ≈ $36.56 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Apotea's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 156.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	Skr832.60 Million	98.65%
Common Stock	Skr500.00K	0.06%
Other Comprehensive Income	Skr-3.80 Million	-0.45%
Other Components	Skr14.70 Million	1.74%
Total Equity	Skr844.00 Million	100.00%

Apotea Competitors by Market Cap

The table below lists competitors of Apotea ranked by their market capitalization.

Company	Market Cap
Berliner Effektengesellschaft AG F:BFV	$952.43 Million
Suzhou Chunqiu Electronic Technology Co Ltd Class A SHG:603890	$952.62 Million
TPK Holding Co Ltd TW:3673	$953.22 Million
Motic Xiamen Electric Group Co Ltd SHE:300341	$953.23 Million
Astra Otoparts Tbk JK:AUTO	$951.75 Million
Healthcare Global Enterprises Limited NSE:HCG	$951.35 Million
Uniphar Group PLC IR:UPR	$951.34 Million
YCC CORP KQ:232140	$951.28 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Apotea's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 55,368,000 to 844,000,000, a change of 788,632,000 (1424.3%).
Net income of 228,700,000 contributed positively to equity growth.
Other comprehensive income decreased equity by 3,602,000.
Other factors increased equity by 563,534,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr228.70 Million	+27.1%
Other Comprehensive Income	Skr-3.60 Million	-0.43%
Other Changes	Skr563.53 Million	+66.77%
Total Change	Skr-	1424.35%

Book Value vs Market Value Analysis

This analysis compares Apotea's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 10.49x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 25.50x to 10.49x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2021-12-31	Skr3.33	Skr85.00	x
2022-12-31	Skr3.15	Skr85.00	x
2023-12-31	Skr0.38	Skr85.00	x
2024-12-31	Skr0.54	Skr85.00	x
2025-12-31	Skr8.11	Skr85.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Apotea utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 27.10%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 3.17%
• Asset Turnover: 3.64x
• Equity Multiplier: 2.35x
Recent ROE (27.10%) is below the historical average (133.99%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2021	30.75%	2.29%	4.45x	3.02x	Skr70.51 Million
2022	6.08%	0.41%	3.90x	3.82x	Skr-12.85 Million
2023	217.88%	1.60%	41.23x	3.31x	Skr83.01 Million
2024	388.13%	3.29%	44.65x	2.65x	Skr209.36 Million
2025	27.10%	3.17%	3.64x	2.35x	Skr144.30 Million

Industry Comparison

This section compares Apotea's net assets metrics with peer companies in the Pharmaceutical Retailers industry.

No peer company data available for comparison.

About Apotea

ST:APOTEA Sweden Pharmaceutical Retailers

Market Cap

$951.97 Million

Skr8.85 Billion SEK

Market Cap Rank

#9092 Global

#146 in Sweden

Share Price

Skr85.00

Change (1 day)

+0.00%

52-Week Range

Skr55.58 - Skr94.57

All Time High

Skr121.14